Scientists Use Ultrasound to Destroy Flu and COVID-19 Viruses Without Harming Human Cells
Researchers in Brazil have demonstrated that high-frequency ultrasound can inactivate influenza A and SARS-CoV-2 viruses while leaving human cells unharmed, opening a potential modern avenue for antiviral treatments. The approach, described in peer-reviewed studies, uses sound waves at frequencies above 20 kHz to mechanically disrupt viral structures—a process likened to “popping” the virus—without damaging surrounding tissue. This method could complement existing therapies by targeting viruses directly in respiratory tracts or on surfaces, though it remains in early laboratory stages.
The findings build on years of investigation into ultrasound’s biological effects, particularly its ability to generate cavitation—microscopic bubble formation and collapse—that can break down pathogens. Unlike chemical disinfectants or drugs that may harm healthy cells or lead to resistance, ultrasound offers a physical mechanism of action that viruses cannot easily evade through mutation. Early experiments show promising results against both H1N1 influenza and SARS-CoV-2, the virus that causes COVID-19, with inactivation rates exceeding 90% under controlled conditions.
One study conducted at the University of São Paulo (USP) exposed aerosolized viruses to ultrasound waves at 40 kHz for three minutes, achieving significant reduction in viral load while maintaining cell viability in human lung cultures. Researchers noted that the treatment did not trigger inflammatory responses or cytotoxicity, suggesting a favorable safety profile for potential topical or inhalable applications. However, they emphasized that these results are preliminary and require validation in animal models and human trials before clinical use.
Another line of research from Brazilian scientists explored ultrasound’s dual action against respiratory viruses and mosquito-borne pathogens like dengue and Zika. By tuning frequency and intensity, they were able to inactivate multiple virus types in laboratory settings, hinting at a broad-spectrum physical antiviral strategy. The team highlighted that ultrasound devices used in the experiments are already approved for other medical purposes, such as physiotherapy and imaging, which could accelerate repurposing if efficacy is confirmed.
Experts caution that while the concept is scientifically plausible, significant hurdles remain. Delivering ultrasound precisely to infected tissues in vivo—especially deep within the lungs—poses engineering challenges. Long-term effects of repeated exposure, optimal dosing regimens, and real-world effectiveness outside controlled lab environments are still unknown. Regulatory pathways for such a novel intervention would also need careful navigation.
Despite these challenges, the research represents a creative shift in antiviral development, moving beyond molecular targets to exploit physical vulnerabilities in viral architecture. As global health systems continue to seek resilient tools against evolving pathogens, non-chemical approaches like ultrasound may offer a valuable addition to the arsenal—provided they are rigorously tested and proven safe.
As of now, no ultrasound-based antiviral treatment has been approved for human use by major health authorities such as the U.S. FDA or Brazil’s ANVISA. Ongoing studies are focused on refining delivery methods and assessing biocompatibility. Researchers involved in the Brazilian projects have not announced timelines for human trials but stress that peer-reviewed publication and independent replication are essential next steps.
For the public, the takeaway remains clear: while ultrasound shows promise in laboratory settings, it is not currently a available treatment for flu or COVID-19. Standard preventive measures—vaccination, ventilation, and hygiene—continue to be the most effective ways to reduce infection risk. Anyone interested in emerging antiviral technologies should follow updates from reputable scientific institutions and peer-reviewed journals.
To share your thoughts on this development or ask questions about emerging antiviral research, join the conversation in the comments below. If you found this article informative, consider sharing it with others who follow innovations in medical science.